31 Jul 2017 11:43
Director/PDMR Shareholding
31 July 2017
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it was advised on 31 July that on that day Dr Andrew Richards, a Non-Executive Director of the Company bought 7,000 Ordinary Shares at 146.88p.
Following this purchase, Dr Richards is interested in 7,000 ordinary shares, 0.01% of the issued share capital of the Company.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities (PDMR) / person closely associated | |||||
a) | Name | Dr Andrew Richards
| ||||
2. | Reason for the notification | |||||
a) | Position / status | PDMR - Non-Executive Director
| ||||
b) | Initial notification / Amendment | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Silence Therapeutics plc
| ||||
b) | LEI | 213800SSURRJBX85SQ91
| ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary Shares in Silence Therapeutics plc
ISIN for Silence Therapeutics plc Ordinary Shares: GB00B9GTXM62
| ||||
b) | Nature of the transaction | Purchase of Ordinary Shares in Silence Therapeutics plc
| ||||
c) | Prices(a) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Price |
7,000 Ordinary Shares £10,282 | ||||
e) | Date of the transaction | 31 July 2017
| ||||
f) | Place of the transaction | London Stock Exchange, AIM
| ||||
Enquiries:
Silence Therapeutics plc Ali Mortazavi, Chief Executive Officer David Ellam, Chief Financial Officer | Tel: +44 (0)20 3457 6900 |
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson
| Tel: +44 (0)20 7418 8900 |
Media Enquiries: FTI Consulting Simon Conway/Brett Pollard/Stephanie Cuthbert
| Tel: +44 (0) 20 3727 1000 |
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
SLN.L (SLN)